Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

MCC response varies based on immunosuppression type, especially CLL

Key clinical point: Patients with Merkel cell carcinoma (MCC) may respond better or worse to immunotherapy depending on how they are immunosuppressed.

Major finding: A total of 18% patients with CLL, 33% with autoimmune disease, 66% with HIV/AIDS and 100% with other hematologic malignancies had an objective response.

Study details: A registry analysis of response rates of 31 patients with MCC and immunosuppression who received immunotherapy.

Disclosures: This study was supported by funding from the MCC Patient Gift Fund, the National Cancer Institute, and a grant from NIH. Ms. Zawacki reports no relevant conflicts of interest.


Zawacki L. SID 2020, Abstract 497.